Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2014

01-07-2014 | Research Article

Association of MTHFR C677T polymorphisms and colorectal cancer risk in Asians: evidence of 12,255 subjects

Authors: X.-P. Guo, Y. Wang, H. Zhao, S.-D. Song, J. Zhou, Y. Han

Published in: Clinical and Translational Oncology | Issue 7/2014

Login to get access

Abstract

Objectives

To investigate the relationship of the MTHFR polymorphisms (C677T) and the risk of CRC by meta-analysis.

Methods

Relevant literatures concerning the association between the MTHFR C677T polymorphism and the risk of CRC were searched using the electronic database PubMed, EMBASE, Cochrane and China National Knowledge Infrastructure (CNKI). Odds ratio (ORs) and 95 % confidence intervals (CIs) were determined to assess the gene–disease association using fixed or random effect models, according to the heterogeneity among included studies.

Results

The study shows that the MTHFR 677 TT homozygous genotype significantly decreases the risk of CRC in Asians (TT vs. CC: OR = 0.82, 95 % CI 0.73–0.92; TT vs. CT: OR = 0.84, 95 % CI 0.75–0.94; TT vs. CC+TT: OR = 0.83, 95 % CI 0.75–0.93).

Conclusion

This meta-analysis indicated that the MTHFR 677 TT homozygous genotype decreased the risk of CRC in Asians, while the MTHFR 677 CT heterozygous genotype did not contribute to CRC susceptibility.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Theodoratou E, Montazeri Z, Hawken S, Allum GC, Gong J, Tait V, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst. 2012;104:1433–57.PubMedCrossRef
3.
4.
5.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
6.
7.
Park KS, Mok JW, Kim JC. The 677C>T mutation in 5,10-methylenetetrahydrofolate reductase and colorectal cancer risk. Genet Test. 1999;3:233–6.PubMedCrossRef
8.
Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control. 2002;13:239–48.PubMedCrossRef
9.
Matsuo K, Hamajima N, Hirai T, Kato T, Inoue M, Takezaki T. Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev. 2002;3:353–9.PubMed
10.
Yin G, Kono S, Toyomura K, Hagiwara T, Nagano J, Mizoue T, et al. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka colorectal cancer study. Cancer Sci. 2004;95:908–13.PubMedCrossRef
11.
Kim DH, Ahn YO, Lee BH, Tsuji E, Kiyohara C, Kono S. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. Cancer Lett. 2004;216:199–205.PubMedCrossRef
12.
Matsuo K, Ito H, Wakai K, Hirose K, Saito T, Suzuki T, et al. One-carbon metabolism related gene polymorphisms interact with alcohol drinking to influence the risk of colorectal cancer in Japan. Carcinogenesis. 2005;26:2164–71.PubMedCrossRef
13.
Gao C, Toshiro T, Wu JZ, Ding JH, Zhou JN, Liu YT, et al. Correlation of genetic polymorphisms of methylenetetrahydrofolate reductase with susceptibility of colorectal cancer. Chin Cancer Prev Treat. 2005;12:1215–22.
14.
Jiang Q, Chen K, Ma X, Li Q, YU W, Shu G, et al. Diets, polymorphisms of methylenetetrahy-drofolate reductase, and the susceptibility of colon cancer and rectal cancer. Cancer Detect Prev. 2005;29:146–54.PubMedCrossRef
15.
Otani T, Iwasaki M, Hanaoka T, Kobayashi M, Ishihara J, Natsukawa S, et al. Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital based case–control study in Japan. Nutr Cancer. 2005;53:42–50.PubMedCrossRef
16.
Wang J, Gajalakshmi V, Jiang J, Kuriki K, Suzuki S, Nagaya T, et al. Associations between 5,10-methylenetetrahydrofolate reductase codon 677 and 1298 genetic polymorphisms and environmental factors with reference to susceptibility to colorectal cancer: a case–control study in an Indian population. Int J Cancer. 2006;118:991–7.PubMedCrossRef
17.
Chang SC, Lin PC, Lin JK, Yang SH, Wang HS, Li AF. Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers. Int J Colorectal Dis. 2007;22:483–9.PubMedCrossRef
18.
Zeybek U, Yaylim I, Yilmaz H, Agachan B, Ergen A, Arikan S, et al. Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. Cell Biochem Funct. 2007;25:419–22.PubMedCrossRef
19.
Cao HX, Gao CM, Takezaki T, Wu JZ, Ding JH, Liu YT, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase and susceptibility to colorectal cancer. Asian Pac J Cancer Prev. 2008;9:203–8.PubMed
20.
Mokarram P, Naghibalhossaini F, Saberi Firoozi M, Hosseini SV, Lzadpanah A, Salahi H, et al. Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/vitamin B12 status. World J Gastroenterol. 2008;14:3662–71.PubMedCentralPubMedCrossRef
21.
Haghighi MM, Radpour R, Mahmoudi T, Mohebbi SR, Vahedi M, Zali MR. Association between MTHFR polymorphism (C677T) with nonfamilial colorectal cancer. Oncol Res. 2009;18:57–63.PubMedCrossRef
22.
Promthet SS, Pientong C, Ekalaksananan T, Wiangnon S, Poomphakwaen K, Songserm N, et al. Risk factors for colon cancer in Northeastern Thailand: interaction of MTHFR codon 677 and 1298 genotypes with environmental factors. J Epidemiol. 2010;20:329–38.PubMedCentralPubMedCrossRef
23.
Cui LH, Shin MH, Kweon SS, Kim HN, Song HR, Piao JM, et al. Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer in a Korean population. BMC Cancer. 2010;10:236.PubMedCentralPubMedCrossRef
24.
Naghibalhossaini F, Mokarram P, Khalili I, Vasei M, Hosseini SV, Ashktorab H, et al. MTHFR C677T and A1298C variant genotypes and the risk of microsatellite instability among Iranian colorectal cancer patients. Cancer Genet Cytogenet. 2010;197:142–51.PubMedCentralPubMedCrossRef
25.
Chandy S, Sadananda Adiga MN, Ramachandra N, Krishnamoorthy S, Ramaswamy G, Savithri HS, et al. Association of methylenetetrahydrofolate reductase gene polymorphisms colorectal cancer in India. Indian J Med Res. 2010;131:659–64.PubMed
26.
Kim JW, Park HM, Choi YK, Chong SY, Oh D, Kim NK. Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol Rep. 2011;25:167–72.PubMed
27.
Zhu Q, Jin Z, Yuan Y, Lu Q, Ge D, Zong M. Impact of MTHFR gene C677T polymorphism on Bcl-2 gene ethylation and protein expression in colorectal cancer. Scand J Gastroenterol. 2011;46:436–45.PubMedCrossRef
28.
Kang BS, Ahn DH, Kim NK, Kim JW. Relationship between metabolic syndrome and MTHFR polymorphism in colorectal cancer. J Korean Soc Coloproctol. 2011;27:78–82.PubMedCentralPubMedCrossRef
29.
Sameer AS, Shah ZA, Nissar S, Mudassar S, Siddiqi MA. Risk of colorectal cancer associated with the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the Kashmiri population. Genet Mol Res. 2011;10:1200–10.PubMedCrossRef
30.
Prasad VV, Wilkhoo H. Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie. 2011;34:422–6.PubMedCrossRef
31.
Li H, Xu WL, Shen HL, Chen QY, Hui LL, Long LL, et al. Methylenetetrahydrofolate reductase genotypes and haplotypes associated with susceptibility to colorectal cancer in an eastern Chinese Han population. Genet Mol Res. 2011;10:3738–46.PubMedCrossRef
32.
Kim J, Cho YA, Kim DH, Lee BH, Hwang DY, Jeong J, et al. Dietary intake of folate and alcohol, MTHFR C677T polymorphism, and colorectal cancer risk in Korea. Am J Clin Nutr. 2012;95:405–12.PubMedCrossRef
33.
Webb EL, Rudd MF, Sellick GS, El Galta R, Bethke L, Wood W, et al. Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14704 first-degree relatives. Hum Mol Genet. 2006;15:3263–71.PubMedCrossRef
34.
Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B. A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer. 2009;8:43–8.PubMedCrossRef
35.
Fernandez-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, Gonzalez-Aguilera JJ. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int J Colorectal Dis. 2010;25:141–51.PubMedCrossRef
36.
Komlosi V, Hitre E, Pap E, Adleff V, Reti A, Szekely E, et al. SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer. BMC Cancer. 2010;10:525.PubMedCentralPubMedCrossRef
37.
Pardini B, Kumar R, Naccarati A, Prasad RB, Forsti A, Polakova V, et al. MTHFR and MTRR genotype and haplotype analysis and colorectal cancer susceptibility in a case–control study from the Czech Republic. Mutat Res. 2011;721:74–80.PubMedCrossRef
38.
Taioli E, Garza M, Ahn Y, Bishop DT, Bost J, Budai B, et al. Meta-and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol. 2009;170:1207–21.PubMedCentralPubMedCrossRef
39.
Yang Z, Zhang XF, Liu HX, Hao YS, Zhao CL. MTHFR C677T polymorphism and colorectal cancer risk in Asians, a meta-analysis of 21 studies. Asian Pac J Cancer Prev. 2012;13:1203–8.PubMedCrossRef
40.
Liu AY, Scherer D, Poole E, Potter JD, Curtin K, Makar K, et al. Gene–diet-interactions in folate-mediated one-carbon metabolism modify colon cancer risk. Mol Nutr Food Res. 2013;57:721–34.PubMedCrossRef
41.
Pevrin-Biroulet L, Barraud H, Ancel D, Petit-Laurent F, Bigard MA, Gueant JL, et al. Folate metabolism and colorectal carcinogenesis. Gastroenterol Clin Biol. 2004;28:582–92.CrossRef
42.
Kato I, Dnistrian AM, Schwartz M, Toniolo P, Koenig K, Shore RE, et al. Serum folate, homocysteine and colorectal cancer risk in women: a nested case–control study. Br J Cancer. 1999;79:1917–22.PubMedCentralPubMedCrossRef
43.
Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 1998;157:40–4.CrossRef
44.
Kennedy DA, Stern SJ, Moretti ME, Moretti ME, Sarkar M, Adams-Webber T, et al. Folate intake, MTHFR polymorphisms, and the risk of colorectal cancer: a systematic review and meta-analysis. J Cancer Epidemiol. 2012;2012:952508.PubMedCentralPubMedCrossRef
45.
Eussen SJ, Vollset SE, Hustad S, Midttun Q, Meyer K, Fredriksen A, et al. Plasma vitamins B2, B6, and B12, and related genetic variants as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2010;19:2549–61.PubMedCentralPubMedCrossRef
46.
Salanti G, Sanderson S, Higgins JP. Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med. 2005;7:13–20.PubMedCrossRef
Metadata
Title
Association of MTHFR C677T polymorphisms and colorectal cancer risk in Asians: evidence of 12,255 subjects
Authors
X.-P. Guo
Y. Wang
H. Zhao
S.-D. Song
J. Zhou
Y. Han
Publication date
01-07-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 7/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1126-x

Other articles of this Issue 7/2014

Clinical and Translational Oncology 7/2014 Go to the issue

Educational Series – Red Series

Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma

Research Article

Temporal trends of incidence and survival of sarcoma of digestive tract including Gastrointestinal Stromal Tumours (GIST) in two areas of the north-east of Spain in the period 1981–2005: a population-based study

Research Article

Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine

Research Article

Identification of putative target genes for amplification within 11q13.2 and 3q27.1 in esophageal squamous cell carcinoma

Research Article

The significant increase and dynamic changes of the myeloid-derived suppressor cells percentage with chemotherapy in advanced NSCLC patients

Research Article

Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits